诺诚健华(09969)公布中期业绩经调整利润约2.77亿元同比扭亏为盈

智通财经08-24

智通财经APP讯，诺诚健华(09969)公布2026年中期业绩，收益约11.37亿元，同比增长55.46%;经调整利润约2.77亿元，同比扭亏为盈;母公司拥有人应占溢利约2.46亿元，同比扭亏为盈。公告称，收益增长主要是由于药物销售收益的强劲增长，以及与Zenas BioPharma, Inc.(纳斯达克代码： ZBIO)合作所产生的里程碑交付成果。药物销售由截至2025年6月30日止六个月的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2661853227?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-24 17:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661853227","market":"hk","top_or_hot":-1,"title":"诺诚健华(09969)公布中期业绩 经调整利润约2.77亿元 同比扭亏为盈","media":"智通财经","content":"<div>\n<p>智通财经APP讯，诺诚健华(09969)公布2026年中期业绩，收益约11.37亿元，同比增长55.46%;经调整利润约2.77亿元，同比扭亏为盈;母公司拥有人应占溢利约2.46亿元，同比扭亏为盈。公告称，收益增长主要是由于药物销售收益的强劲增长，以及与Zenas BioPharma, Inc.(纳斯达克代码： ZBIO)合作所产生的里程碑交付成果。药物销售由截至2025年6月30日止六个月的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1484265.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺诚健华(09969)公布中期业绩 经调整利润约2.77亿元 同比扭亏为盈</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺诚健华(09969)公布中期业绩 经调整利润约2.77亿元 同比扭亏为盈\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-24 17:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1484265.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，诺诚健华(09969)公布2026年中期业绩，收益约11.37亿元，同比增长55.46%;经调整利润约2.77亿元，同比扭亏为盈;母公司拥有人应占溢利约2.46亿元，同比扭亏为盈。公告称，收益增长主要是由于药物销售收益的强劲增长，以及与Zenas BioPharma, Inc.(纳斯达克代码： ZBIO)合作所产生的里程碑交付成果。药物销售由截至2025年6月30日止六个月的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1484265.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1484265.html","article_id":"2661853227","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661853227","pubTimestamp":1787564375,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，诺诚健华 公布2026年中期业绩，收益约11.37亿元，同比增长55.46%;经调整利润约2.77亿元，同比扭亏为盈;母公司拥有人应占溢利约2.46亿元，同比扭亏为盈。于报告期内，诺诚健华进一步推进其多产品、多领域的战略，在血液肿瘤、自身免疫性疾病及实体瘤领域的贡献持续扩大。随着多项产品商业化或即将提交监管申请，诺诚健华已迈入多元化增长的新阶段，不仅提升了盈利可预测性，更扩大全球业务布局。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","BK1161":"生物科技","BK1574":"生物医药B类股","09969":"诺诚健华"},"translate_title":"InnoCare (09969) announced its interim results with adjusted profit of about 277 million yuan, turning losses into profits year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1.5,"09969":1.5},"content_text":"智通财经APP讯，诺诚健华(09969)公布2026年中期业绩，收益约11.37亿元，同比增长55.46%;经调整利润约2.77亿元，同比扭亏为盈;母公司拥有人应占溢利约2.46亿元，同比扭亏为盈。公告称，收益增长主要是由于药物销售收益的强劲增长，以及与Zenas BioPharma, Inc.(纳斯达克代码： ZBIO)合作所产生的里程碑交付成果。药物销售由截至2025年6月30日止六个月的6.41亿元增加43.2%至9.18亿元，主要是由于奥布替尼持续的强劲增长以及坦昔妥单抗和佐来曲替尼的新上市。于报告期内，诺诚健华进一步推进其多产品、多领域的战略，在血液肿瘤、自身免疫性疾病及实体瘤领域的贡献持续扩大。多项资产迈向或已达成关键监管与临床里程碑，为持续长期增长奠定坚实基础。随着多项产品商业化或即将提交监管申请，诺诚健华已迈入多元化增长的新阶段，不仅提升了盈利可预测性，更扩大全球业务布局。凭借严谨的执行力及产品组合扩展，公司具备可持续创造价值的充分优势。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661853227","isCrawlerRequest":true}

诺诚健华(09969)公布中期业绩 经调整利润约2.77亿元 同比扭亏为盈

精彩评论

诺诚健华(09969)公布中期业绩经调整利润约2.77亿元同比扭亏为盈